Two-year outcomes of everolimus vs. paclitaxel-eluting stent for the treatment of unprotected left main lesions: a propensity score matching comparison of patients included in the French Left Main Taxus (FLM Taxus) and the LEft MAin Xience (LEMAX) registries

Abstract

ULM stenting with EES is safer and more effective than PES with a reduction in TLF by 53% at two years.

Second vs. First generation drug eluting stents in multiple vessel disease and left main stenosis: Two‐year follow‐up of the observational, prospective, controlled, and multicenter ERACI IV registry

“…Our low events rate were in agreement with several randomized and observational studies comparing 2nd or 3rd generation DES versus the first ones , although limited information has been reported so far in patients with complex lesion subsets such as we are reporting here . The 2nd and 3rd generation DES showed significant improvement in stent design, polymer characteristics, drug release and stent struts coverage, and all of these new features significantly enhanced the safety/efficacy compared to previous ones .…”

“…In that study, there was an incidence of the primary end point of MACCE at 1 year of follow‐up among patients treated with 1st generation DES (12% of MACCE and 7% of death/MI/CVA). Taking into account that second generation DES—either Xcience V (Abbott,Vascular), Promus Element (Boston Scientific), or Endeavor Resolute (Medtronic)—compared to the 1st generation ones, Taxus Express or Taxus Element (Boston Scientific) in most cases, reported a reduction of major adverse events of 50% during the first and second year , using a two‐sided test for differences in independent binomial proportions with a level of 0.05, we estimated that if we included 225 patients, the power of the study would be 80% to detect differences between both kind of stents. Continuous variables were compared using ANOVA with Bonferroni correction.…”

“…One of the major limitations in these studies was the fact that they were performed generally in well selected low risk populations and there is limited information at the present time on whether these new devices will also be able to improve outcome in patients such as those included in SYNTAX and FREEDOM, with multiple vessel CAD, unprotected left main, diabetes and/or with intermediate or high Syntax Score (SS).…”

Comparison of first- and second-generation drug-eluting stent efficacies for treating left main and/or three-vessel disease: a propensity matched study

“…Moynagh et al [10] reported a propensity score matching comparison between PES and EES for the treatment of unprotected left main disease, however we compared firstgeneration DES and second-generation DES for treating not only LM but also 3VD using propensity matching according to SYNTAX scores. The main findings of our study are:…”

A Tale of Two Techniques: Demystifying the Myth

“…It is important to note that improved clinical outcomes with the everolimus-eluting stent --the most used stent in Nfor et al's study (~59% 32 ) --in multivessel disease, 37 coupled with similarly reported data from the French Left Main Taxus and LEMAX registries that investigated left main stenting with everolimus-eluting stents 38,39 and the known reductions in stent thrombosis of newer-generation DES, [40][41][42][43][44][45][46][47] implies that if newergeneration DES had been used in the SYNTAX trial, there would have been a significant reduction in repeat revascularization and myocardial infarction. It is also plausible that reductions in mortality would have been seen with the newer-generation DES.…”